Survival Benefits of Statins for Primary Prevention: A Cohort Study

Published Paper

Survival Benefits of Statins for Primary Prevention: A Cohort Study

  • Authors: Gitsels , Lisanne A., Kulinskaya, Elena., Steel, Nicholas,.
  • Journal: PLOS ONE.
Abstract:
Estimate the effect of statin prescription on mortality in the population of England and Wales with no previous history of cardiovascular disease. Primary care records from The Health Improvement Network 1987–2011 were used. Four cohorts of participants aged 60, 65, 70, or 75 years at baseline included 118,700, 199,574, 247,149, and 194,085 participants; and 1.4, 1.9, 1.8, and 1.1 million person-years of data, respectively. The exposure was any statin prescription at any time before the participant reached the baseline age (60, 65, 70 or 75) and the outcome was all-cause mortality at any age above the baseline age. The hazard of mortality associated with statin prescription was calculated by Cox’s proportional hazard regressions, adjusted for sex, year of birth, socioeconomic status, diabetes, antihypertensive medication, hypercholesterolaemia, body mass index, smoking status, and general practice. Participants were grouped by QRISK2 baseline risk of a first cardiovascular event in the next ten years of <10%, 10–19%, or ≥20%.

Read more and download the full paper.